Immuno-oncology
Conference Coverage
PACIFIC: Patient-reported outcomes unaffected by PD-L1 expression
GENEVA – Level of programmed death-ligand 1 expression does not impact patient-reported outcomes among those...
Conference Coverage
Factors emerge for mitigating CD19 CAR T toxicity
HOUSTON – Cytokine release syndrome and neurotoxicity are common complications related to CD19-directed CAR T-cell immunotherapies, but research...
Conference Coverage
ENCORE-601: Entinostat/pembrolizumab safe, active for melanoma
ATLANTA – Combined therapy with the HDAC inhibitor entinostat and the PD-1 inhibitor pembrolizumab has significant clinical activity and...
Conference Coverage
Creating CAR T-cell therapies for T-cell malignancies
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
Conference Coverage
Novel CAR T, anti-PD-1 combo shows promise in MPD
ATLANTA – Intrapleurally administered, mesothelin-targeted CAR T-cell therapy combined with PD-1 inhibition showed antitumor activity without...
From the Journals
Immunotherapy overtaking breast cancer treatment landscape
Review authors suggest combination therapy strategies will be the way forward for immunotherapy in breast cancer, with an improved understanding...
Conference Coverage
Pooled KEYNOTE data support pembro for elderly patients with NSCLC
GENEVA – Investigators analyzed data from 264 patients 75 years or older involved in the KEYNOTE-010, KEYNOTE-024,...
News
FDA approves pembrolizumab for first-line stage III NSCLC
Approval was based on improved overall survival for patients taking pembrolizumab, compared with those taking the investigators’ choice of...
Conference Coverage
Dr. Louis Weiner: AACR presentations highlight new “transformative strategies”
ATLANTA – Studies featured during a press briefing at the AACR annual meeting, including work on a cancer preventive...
Conference Coverage
Preclinical findings highlight value of Lynch syndrome for cancer vaccine development
ATLANTA – Lynch syndrome is serving as a platform for the development of immunoprevention cancer vaccines.
Conference Coverage
CAR T cells target HER2 expression in advanced sarcomas
ATLANTA – Although HER2 expression in osteosarcoma and rhabomyosarcoma is too low for HER2-targeted therapies such...